

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China Regenerative Medicine International Limited**

**中國再生醫學國際有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8158)**

**(1) EFFECTIVE DATE OF THE CAPITAL REDUCTION AND  
THE SHARE SUB-DIVISION;  
(2) FREE EXCHANGE OF SHARE CERTIFICATES; AND  
(3) UPDATE ON CONNECTED TRANSACTION –  
LOAN CAPITALISATION INVOLVING ISSUE OF SHARES  
UNDER SPECIFIC MANDATE**

References are made to (i) the announcement of China Regenerative Medicine International Limited (the “**Company**”) dated 14 July 2023; (ii) the circular (the “**Circular**”) of the Company dated 18 August 2023; (iii) the poll results announcement of extraordinary general meeting of the Company dated 4 September 2023; (iv) the announcement of the Company dated 12 October 2023; and (v) the announcement of the Company dated 25 October 2023, in relation to, among other things, Capital Reorganisation. Capitalised terms used in this announcement shall have the same meaning as those used in the Circular unless otherwise defined.

### **EFFECTIVE DATE OF THE CAPITAL REDUCTION AND THE SHARE SUB-DIVISION**

The Board is pleased to announce that a copy of the order of the Grand Court confirming the Capital Reduction and the Share Sub-division and the minute approved by the Grand Court containing the particulars required under the Companies Act with respect to the Capital Reduction were filed and duly registered with the Registrar of Companies in the Cayman Islands on 6 December 2023 (Cayman Islands time). The Company further announces that all the other conditions for the implementation of the Capital Reduction and the Share Sub-division as set out in the Circular have been fulfilled. The Capital Reduction and the Share Sub-division will become effective before 9:00 a.m. on Thursday, 7 December 2023 (Hong Kong time) and the dealing in the New Shares will commence at 9:00 a.m. on Thursday, 7 December 2023 (Hong Kong time).

## **FREE EXCHANGE OF SHARE CERTIFICATES**

Shareholders may, between 9:00 a.m. and 4:00 p.m. on any Business Day during the period from Thursday, 7 December 2023 to Friday, 12 January 2024 (both days inclusive), submit existing share certificates for the Consolidated Shares (in purple colour) to the Company's Hong Kong Branch Share Registrar, Union Registrars Limited at Suites 3301–04, 33/F, Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong to exchange for new share certificates for the New Shares (in green colour) at the expense of the Company. All existing certificates of the Consolidated Shares will continue to be evidence of title to such Shares and be valid for delivery, trading and settlement purpose.

## **UPDATE ON CONNECTED TRANSACTION – LOAN CAPITALISATION INVOLVING ISSUE OF SHARES UNDER SPECIFIC MANDATE**

Pursuant to the Subscription Agreement and the supplemental agreement entered into between the Company and the Subscriber dated 12 October 2023, Completion will take place within five Business Days after the date on which all the conditions to the Subscription Agreement are satisfied (or such other date as the Company and the Subscriber may agree in writing). Completion is expected to take place on or around 13 December 2023.

**Shareholders and potential investors are advised to exercise caution when dealing in the Shares of the Company, and if they are in any doubt about their position, they should consult their professional advisers. The Company will make further announcement(s) with regard to the status of the abovementioned transactions as and when appropriate.**

By Order of the Board  
**China Regenerative Medicine International Limited**  
**Khoo Wun Fat William**  
*Company Secretary*

Hong Kong, 7 December 2023

*As at the date of this announcement, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Mr. Tsang Ho Yin; and the independent non-executive Directors are Ms. Huo Chunyu, Dr. Liu Ming and Mr. Leung Man Fai.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of its publication. This announcement will also be published on the Company’s website at [www.crmi.hk](http://www.crmi.hk).*

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*